Skip to main content

Table 4 Participant demographics for control and progesterone groups

From: The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk

  High risk controls Progesterone Total
n/N (%) 42/67 (63%) 25/67(37%) 67/67 (100%)
Age, years
 Mean ± SD (range) 32 ± 5.5 (21–40) 32 ± 3.9 (22–38) 32 ± 5.0 (21–40)
BMI
 Mean ± SD (range) 24.7 ± 5.3 (19–48) 25.2 ± 4.7 (18.4–35) 24.9 ± 5.0 (18.4–48)
Ethnicity, n/N (%)
 Caucasian 32/42 (76%) 18/25 (72%) 50/67 (75%)
 Asian 4/42 (10%) 3/25 (12%) 7/67 (10%)
 Black 6/42 (14%) 4/25 (16%) 10/67 (15%)
Smoker n/N (%) 2/42 (5%) 0/25 (0%) 2/67 (3%)
Screening for progesterone    
 GA (weeks), median, range 15+0 (12+1–18+2) 15+6 (12+0–18+6) 15+3 (12+0–18+6)
 CL (mm), median, range 32 (26–43) 22 (13–25) (13–43)
Gestation at delivery, n/N (%)
 Early PTB, <34+0 weeks 1/42 (2%) 4/25 (16%) 5/67 (7%)
 Late PTB, 34+0 to <37+0 weeks 1/42 (2%) 4/25 (16%) 5/67 (7%)
 Term, ≥37+0 weeks 40/42 (95%) 17/25 (68%) 57/67 (85%)
  1. PTB preterm birth, GA gestational age, CL cervical length (mm)